Active substance
Metformin
- SFDA 59
- US FDA 110
- Health Canada 47
- US price lines 12
- NHS prices 13
- WHO EML 1
- Safety 28
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| DIALON 1000MG F.C. TABLETS | 1000 mg | Film-coated tablet · Oral use | 30 Blister | SAR 6.95 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| DIALON 500 MG F.C TAB | 500 mg | Film-coated tablet · Oral use | 48 Blister | SAR 6.05 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| DIALON 850MG F.C. TABLETS | 850 mg | Film-coated tablet · Oral use | 30 Blister | SAR 3.80 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| DIAPHAGE 1 G SR TABLET | 1000 mg | Tablet · Oral use | 28 Blister | SAR 23.80 | Generic · Prescription | UNITED PHARMACEUTICAL CO. | Valid |
| Diafor XR | 1000 mg | Prolonged-release tablet · Oral use | 56 Blister | SAR 52.85 | Generic · Prescription | Saudi Amarox | Valid |
| Diafor XR | 750 mg | Prolonged-release tablet · Oral use | 56 Blister | SAR 39.65 | Generic · Prescription | Saudi Amarox | Valid |
| Diafor XR | 500 mg | Prolonged-release tablet · Oral use | 56 Blister | SAR 26.45 | Generic · Prescription | Saudi Amarox | Valid |
| Diafor XR | 1000 mg | Prolonged-release tablet · Oral use | 28 Blister | SAR 26.45 | Generic · Prescription | Saudi Amarox | Valid |
| Diafor XR | 750 mg | Prolonged-release tablet · Oral use | 28 Blister | SAR 19.85 | Generic · Prescription | Saudi Amarox | Valid |
| Diafor XR | 500 mg | Prolonged-release tablet · Oral use | 28 Blister | SAR 13.20 | Generic · Prescription | Saudi Amarox | Valid |
| FORMIT 850 MG TABLETS | 850 mg | Tablet · Oral use | 60 Blister | SAR 26.15 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| FORMIT XR 750 MG TABLETS | 750 mg | Extended-release tablet · Oral use | 30 Blister | SAR 22.50 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| FORMIT XR 750 MG TABLETS | 750 mg | Extended-release tablet · Oral use | 60 Blister | SAR 45.00 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| Formit XR | 500 mg | Extended-release tablet · Oral use | 30 Blister | SAR 12.50 | Generic · Prescription | SPIMACO | Valid |
| Formit XR | 500 mg | Extended-release tablet · Oral use | 60 Blister | SAR 25.00 | Generic · Prescription | SPIMACO | Valid |
| GLUCARE 1000 mg XR Tablet | 1000 mg | Extended-release tablet · Oral use | 60 Blister | SAR 56.65 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| GLUCARE 500MG TAB | 500 mg | Film-coated tablet · Oral use | 50 Blister | SAR 14.90 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| GLUCARE 850 TAB. | 850 mg | Film-coated tablet · Oral use | 60 Blister | SAR 27.75 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| GLUCARE XR 500 mg tablet | 500 mg | Extended-release tablet · Oral use | 30 Blister | SAR 15.85 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| GLUCARE XR 500 mg tablet | 500 mg | Extended-release tablet · Oral use | 60 Blister | SAR 31.70 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| GLUCARE XR 500 mg tablet | 500 mg | Extended-release tablet · Oral use | 90 Blister | SAR 47.55 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| GLUCARE XR 750 mg tablet | 750 mg | Extended-release tablet · Oral use | 30 Blister | SAR 23.75 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| GLUCARE XR 750 mg tablet | 750 mg | Extended-release tablet · Oral use | 60 Blister | SAR 47.50 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| GLUCOPHAGE 1 g tablet | 1000 mg | Film-coated tablet · Oral use | 30 Blister | SAR 19.85 | NCE · Prescription | MERCK SANTE | Valid |
| GLUCOPHAGE 500 mg tablet | 500 mg | Film-coated tablet · Oral use | 60 Blister | SAR 19.85 | Generic · Prescription | MERCK SANTE | Valid |
34 more — full table
Indications — CHI Daman Drug Formulary
DIABETES MELLITUS TYPE 2; GESTATIONAL DIABETES
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| METFORMIN HYDROCHLORIDE | 500MG; 850MG; 1GM; 750MG; 625MG | tablet · oral | CHARTWELL | Prescription | 24 Jan 2002 |
| METFORMIN HYDROCHLORIDE | 500MG; 850MG; 1GM | tablet · oral | SENORES PHARMS | Prescription | 24 Jan 2002 |
| METFORMIN HYDROCHLORIDE | 500MG; 850MG; 1GM | tablet · oral | EPIC PHARMA LLC | Prescription | 25 Jan 2002 |
| METFORMIN HYDROCHLORIDE | 500MG; 850MG; 1GM | tablet · oral | MYLAN | Prescription | 25 Jan 2002 |
| METFORMIN HYDROCHLORIDE | 500MG | tablet, extended release · oral | TEVA | Prescription | 18 Jun 2004 |
| METFORMIN HYDROCHLORIDE | 500MG | tablet, extended release · oral | SANDOZ | Prescription | 14 Dec 2004 |
| METFORMIN HYDROCHLORIDE | 500MG; 850MG; 1GM | tablet · oral | AUROBINDO | Prescription | 14 Jan 2005 |
| METFORMIN HYDROCHLORIDE | 750MG | tablet, extended release · oral | TEVA | Prescription | 12 Apr 2005 |
| METFORMIN HYDROCHLORIDE | 750MG | tablet, extended release · oral | ACTAVIS LABS FL INC | Prescription | 12 Apr 2005 |
| METFORMIN HYDROCHLORIDE | 500MG; 850MG; 1GM | tablet · oral | ZYDUS PHARMS USA | Prescription | 18 Apr 2005 |
| METFORMIN HYDROCHLORIDE | 500MG | tablet, extended release · oral | ZYDUS LIFESCIENCES | Prescription | 20 Apr 2005 |
| METFORMIN HYDROCHLORIDE | 750MG | tablet, extended release · oral | ZYDUS LIFESCIENCES | Prescription | 21 Apr 2005 |
| METFORMIN HYDROCHLORIDE | 500MG; 750MG | tablet, extended release · oral | NOSTRUM PHARMS LLC | Prescription | 26 Jul 2006 |
| METFORMIN HYDROCHLORIDE | 500MG; 850MG; 1GM | tablet · oral | DR REDDYS LABS INC | Prescription | 23 Aug 2006 |
| METFORMIN HYDROCHLORIDE | 500MG; 750MG | tablet, extended release · oral | CSPC OUYI | Prescription | 17 Apr 2008 |
| METFORMIN HYDROCHLORIDE | 500MG; 850MG; 1GM | tablet · oral | GRANULES INDIA | Prescription | 22 Apr 2010 |
| METFORMIN HYDROCHLORIDE | 500MG; 850MG; 1GM | tablet · oral | ALKEM | Prescription | 1 Nov 2010 |
| METFORMIN HYDROCHLORIDE | 500MG; 1GM | tablet, extended release · oral | LUPIN LTD | Prescription | 29 Jun 2011 |
| METFORMIN HYDROCHLORIDE | 500MG | tablet, extended release · oral | ADAPTIS | Prescription | 18 Jan 2012 |
| METFORMIN HYDROCHLORIDE | 500MG; 850MG; 1GM | tablet · oral | PHARMAZONE | Prescription | 12 Mar 2012 |
| METFORMIN HYDROCHLORIDE | 500MG; 750MG | tablet, extended release · oral | AUROBINDO PHARMA LTD | Prescription | 20 Jul 2012 |
| METFORMIN HYDROCHLORIDE | 500MG; 1GM | tablet, extended release · oral | MYLAN PHARMS INC | Prescription | 1 Aug 2012 |
| METFORMIN HYDROCHLORIDE | 500MG; 1GM | tablet, extended release · oral | LUPIN | Prescription | 19 Jul 2013 |
| METFORMIN HYDROCHLORIDE | 500MG; 850MG; 1GM; 625MG; 750MG | tablet · oral | SCIEGEN PHARMS | Prescription | 11 Sep 2013 |
| METFORMIN HYDROCHLORIDE | 500MG; 850MG; 1GM | tablet · oral | ZYDUS HLTHCARE | Prescription | 28 Aug 2014 |
85 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AG-METFORMIN | 02494418 | 500 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| AG-METFORMIN | 02494442 | 850 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| APO-METFORMIN ER | 02305062 | 500 MG | TABLET (EXTENDED-RELEASE) · ORAL | APOTEX INC |
| APO-METFORMIN ER | 02460653 | 1000 MG | TABLET (EXTENDED-RELEASE) · ORAL | APOTEX INC |
| AURO-METFORMIN | 02438275 | 500 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-METFORMIN | 02438283 | 850 MG | TABLET · ORAL | AURO PHARMA INC |
| GLUCOPHAGE | 02099233 | 500 MG | TABLET · ORAL | SANOFI-AVENTIS CANADA INC |
| GLUMETZA | 02268493 | 500 MG | TABLET (EXTENDED-RELEASE) · ORAL | BAUSCH HEALTH, CANADA INC. |
| GLUMETZA | 02300451 | 1000 MG | TABLET (EXTENDED-RELEASE) · ORAL | BAUSCH HEALTH, CANADA INC. |
| JAMP METFORMIN | 02380196 | 500 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP METFORMIN | 02380218 | 850 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| M-METFORMIN | 02547767 | 500 MG | TABLET · ORAL | MANTRA PHARMA INC |
| M-METFORMIN | 02547775 | 850 MG | TABLET · ORAL | MANTRA PHARMA INC |
| M-METFORMIN | 02548275 | 1000 MG | TABLET · ORAL | MANTRA PHARMA INC |
| M-METFORMIN XR | 02551845 | 500 MG | TABLET (EXTENDED-RELEASE) · ORAL | MANTRA PHARMA INC |
| M-METFORMIN XR | 02551853 | 1000 MG | TABLET (EXTENDED-RELEASE) · ORAL | MANTRA PHARMA INC |
| MAR-METFORMIN | 02378620 | 500 MG | TABLET · ORAL | MARCAN PHARMACEUTICALS INC |
| MAR-METFORMIN | 02378639 | 850 MG | TABLET · ORAL | MARCAN PHARMACEUTICALS INC |
| MAR-METFORMIN XR | 02550504 | 500 MG | TABLET (EXTENDED-RELEASE) · ORAL | MARCAN PHARMACEUTICALS INC |
| MAR-METFORMIN XR | 02550512 | 1000 MG | TABLET (EXTENDED-RELEASE) · ORAL | MARCAN PHARMACEUTICALS INC |
| METFORMIN | 02353377 | 500 MG | TABLET · ORAL | SANIS HEALTH INC |
| METFORMIN | 02353385 | 850 MG | TABLET · ORAL | SANIS HEALTH INC |
| METFORMIN | 02385341 | 500 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| METFORMIN | 02385368 | 850 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| METFORMIN ER | 02558785 | 500 MG | TABLET (EXTENDED-RELEASE) · ORAL | SANIS HEALTH INC |
22 more — full table
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | METFORMIN ER 1,000 MG GASTR-TB | $0.3357 | per EA | 23 Sep 2026 |
| US NADAC | METFORMIN ER 1,000 MG OSM-TAB | $0.31418 | per EA | 23 Sep 2026 |
| US NADAC | METFORMIN ER 500 MG GASTRC-TB | $0.27102 | per EA | 23 Sep 2026 |
| US NADAC | METFORMIN ER 500 MG OSMOTIC TB | $0.1644 | per EA | 23 Sep 2026 |
| US NADAC | METFORMIN HCL 1,000 MG TABLET | $0.02315 | per EA | 23 Sep 2026 |
| US NADAC | METFORMIN HCL 500 MG TABLET | $0.01451 | per EA | 23 Sep 2026 |
| US NADAC | METFORMIN HCL 500 MG/5 ML SOLN | $0.3829 | per ML | 23 Sep 2026 |
| US NADAC | METFORMIN HCL 625 MG TABLET | $12.5266 | per EA | 25 Feb 2026 |
| US NADAC | METFORMIN HCL 750 MG TABLET | $14.605 | per EA | 25 Feb 2026 |
| US NADAC | METFORMIN HCL 850 MG TABLET | $0.02398 | per EA | 23 Sep 2026 |
| US NADAC | METFORMIN HCL ER 500 MG TABLET | $0.02838 | per EA | 23 Sep 2026 |
| US NADAC | METFORMIN HCL ER 750 MG TABLET | $0.05264 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Metformin 1g modified-release tablets | £2.26 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Metformin 1g oral powder sachets sugar free | £12.60 | 30 sachet | 1 Oct 2026 |
| NHS Drug Tariff | Metformin 1g tablets | £2.38 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Metformin 1g/5ml oral solution sugar free | £80.00 | 150 ml | 1 Oct 2026 |
| NHS Drug Tariff | Metformin 500mg modified-release tablets | £1.73 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Metformin 500mg oral powder sachets sugar free | £12.60 | 30 sachet | 1 Oct 2026 |
| NHS Drug Tariff | Metformin 500mg tablets | £0.67 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Metformin 500mg/5ml oral solution sugar free | £6.58 | 150 ml | 1 Oct 2026 |
| NHS Drug Tariff | Metformin 750mg modified-release tablets | £1.14 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Metformin 750mg modified-release tablets | £2.29 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Metformin 850mg modified-release tablets | £3.20 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Metformin 850mg tablets | £1.02 | 56 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 18.5.2. Hypoglycaemic agents · core (EML); complementary (EMLc)
Type 2 diabetes mellitus
Oral > Solid: 500 mg (hydrochloride)
Safety signals and safety-related labeling changes
- US FDA 11 Aug 2026 ACTOPLUS MET — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 11 Aug 2026 FORTAMET — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 11 Aug 2026 GLUMETZA — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 11 Aug 2026 INVOKAMET — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 11 Aug 2026 INVOKAMET XR — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 11 Aug 2026 JANUMET — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 11 Aug 2026 JANUMET XR — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 11 Aug 2026 JENTADUETO — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 11 Aug 2026 JENTADUETO XR — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 11 Aug 2026 KAZANO — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 11 Aug 2026 KOMBIGLYZE XR — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 11 Aug 2026 RIOMET ER — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 11 Aug 2026 SEGLUROMET — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 11 Aug 2026 SYNJARDY — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 11 Aug 2026 SYNJARDY XR — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Combinations containing Metformin
- Alogliptin + metformin
- Canagliflozin + metformin
- Dapagliflozin + metformin
- Empagliflozin + metformin
- Ertugliflozin + metformin
- Glibenclamide + metformin
- Glimepiride + metformin
- Linagliptin + metformin
- Metformin + pioglitazone
- Metformin + rosiglitazone
- Metformin + saxagliptin
- Metformin + sitagliptin
- Metformin + vildagliptin
- Dapagliflozin + metformin + saxagliptin
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.